11 studies found for:    SAILS
Show Display Options
Rank Status Study
1 Recruiting Virtual Sailing Simulator in Individuals With Spinal Cord Injury
Condition: Spinal Cord Injury
Intervention: Device: The VSail-Access simulator
2 Recruiting Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Intervention: Drug: sirolimus and hydroxychloroquine
3 Active, not recruiting Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials
Condition: Respiratory Distress Syndrome, Adult
Intervention:
4 Recruiting Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin
Condition: Type 2 Diabetes
Interventions: Drug: liraglutide;   Drug: placebo injection
5 Recruiting Sustained Aeration of Infant Lungs Trial
Conditions: Preterm Birth;   Extreme Prematurity
Interventions: Procedure: Sustained Inflation;   Procedure: Standard of Care
6 Terminated
Has Results
Statins for Acutely Injured Lungs From Sepsis
Conditions: Sepsis;   Acute Lung Injury
Interventions: Drug: Rosuvastatin;   Drug: Placebo
7 Recruiting Safety of Intravenous Thrombolytics in Stroke on Awakening
Condition: Stroke
Intervention: Drug: rt-PA
8 Active, not recruiting
Has Results
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: Raltegravir;   Drug: GSK1349572 Placebo;   Drug: Raltegravir Placebo
9 Not yet recruiting Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)
Condition: Diabetic Macular Edema
Interventions: Drug: Conbercept;   Other: Sham injection;   Procedure: Laser;   Other: Sham laser
10 Recruiting A Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML
Condition: Acute Myeloid Leukemia (Relapsed/Refractory)
Interventions: Drug: Selinexor;   Drug: Idarubcin;   Drug: Cytarabine
11 Completed Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week
Condition: Healthy
Intervention:

Indicates status has not been verified in more than two years